Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVRO: Vernakalant vs Amiodarone in Recent Onset AF
NCT00668759Phase 3Completed
- Sponsor
- ADVANZ PHARMA
- Start
- Apr 2008
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of vernakalant in Atrial fibrillation (AFib) (2 arms), sponsored by ADVANZ PHARMA. Primary endpoint: Proportion of subjects with conversion of atrial fibrillation to sinus rhythm. Started Apr 2008; status: completed.
02
Drugs
vernakalant
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00668759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00668759.